Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
about
Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Safety, tolerability and pharm ...... gle-dose first-in-human study.
@ast
Safety, tolerability and pharm ...... gle-dose first-in-human study.
@en
type
label
Safety, tolerability and pharm ...... gle-dose first-in-human study.
@ast
Safety, tolerability and pharm ...... gle-dose first-in-human study.
@en
prefLabel
Safety, tolerability and pharm ...... gle-dose first-in-human study.
@ast
Safety, tolerability and pharm ...... gle-dose first-in-human study.
@en
P2093
P2860
P1476
Safety, tolerability and pharm ...... ngle-dose first-in-human study
@en
P2093
Alexa Piantone
Bart van Hartingsveldt
Esther Bouman-Thio
Hugh M Davis
Ivo P Nnane
Kevin J Petty
P2860
P304
P356
10.1111/J.1365-2125.2012.04477.X
P407
P577
2013-05-01T00:00:00Z